Pulmonx Corporation (LUNG) Earnings Call Analysis

NASDAQ · Healthcare · Medical Devices

12/25

Growth 3 Margin 2 Expansion 4 Platform 0 Financial 3

latest quarter score

Earnings Reports

12
Pulmonx (LUNG) Q2 2026: Cash Flow Break-Even Path Secured by Expanded Debt Facility
July 30, 2026
9
Pulmonx (LUNG) Q1 2026: U.S. Treating Centers Expand by 15 as Sales Force Rebuild Drives Transition Year
April 30, 2026
9
Pulmonx (LUNG) Q4 2025: Operating Expenses Cut 10% as U.S. Sales Force Rebuilds for Back-Half Rebound
March 05, 2026
7
Pulmonx (LUNG) Q3 2025: U.S. Revenue Growth Slows to 1% as Leadership Signals Cost Discipline
November 13, 2025
14
Pulmonx (LUNG) Q2 2025: International Revenue Jumps 32% as U.S. Ramp Lags Guidance Reset
July 30, 2025
12
Palmonix (LUNG) Q1 2025: International Revenue Surges 39% as U.S. Initiatives Target Growth Reacceleration
July 04, 2025

Browse all companies